Aviceda Therapeutics has launched biotech financing in 2025 with a $207.5m raise to advance its lead drug for geographic atrophy, a sight-threatening disease, into pivotal trials.
The Series C round, co-led by Omega Funds and TCGX, will support the ongoing phase 2/3 SIGLEC trial of AVD-104 for geographic atrophy linked to age-related macular degeneration.
The trial is expected to deliver results in the second half of the year, with funding also allocated to a phase 3 programme if progress stays on track.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
The funding round also saw participation from investment firms including Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, and Digitalis Ventures.
Source: Pharmaphorum
Can’t stop reading? Read more
Top private equity news of the week
Top private equity news of the week Soho House, the global private members’ club and hotel group,...
Audax turns to Blackstone as Justrite seeks $700m private credit lifeline
Audax turns to Blackstone as Justrite seeks $700m private credit lifeline Audax Private Equity is...
Mitsubishi takes stake in RRJ-backed Fullerton Health to fuel Southeast Asia growth
Mitsubishi takes stake in RRJ-backed Fullerton Health to fuel Southeast Asia growth Mitsubishi...